Literature DB >> 27834353

Combinatorial immunotherapy for melanoma.

D D George1, V A Armenio2,3, S C Katz4,5.   

Abstract

Melanoma has been a long-standing focal point for immunotherapy development. In this review, we explore the evolution of melanoma treatments with particular attention to the history and recent advances in melanoma immunotherapy. We also discuss novel combinations of these modalities and their potential to offer novel therapeutic options for patients with advanced melanoma.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27834353     DOI： 10.1038/cgt.2016.56

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


  53 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

3.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 4.  Immune checkpoint blockade: a common denominator approach to cancer therapy.

Authors:  Suzanne L Topalian; Charles G Drake; Drew M Pardoll
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

5.  Genomic Classification of Cutaneous Melanoma.

Authors: 
Journal:  Cell       Date:  2015-06-18       Impact factor: 41.582

6.  Final trial report of sentinel-node biopsy versus nodal observation in melanoma.

Authors:  Donald L Morton; John F Thompson; Alistair J Cochran; Nicola Mozzillo; Omgo E Nieweg; Daniel F Roses; Harold J Hoekstra; Constantine P Karakousis; Christopher A Puleo; Brendon J Coventry; Mohammed Kashani-Sabet; B Mark Smithers; Eberhard Paul; William G Kraybill; J Gregory McKinnon; He-Jing Wang; Robert Elashoff; Mark B Faries
Journal:  N Engl J Med       Date:  2014-02-13       Impact factor: 91.245

7.  Comparison of clinicopathologic features and survival of histopathologically amelanotic and pigmented melanomas: a population-based study.

Authors:  Nancy E Thomas; Anne Kricker; Weston T Waxweiler; Patrick M Dillon; Klaus J Busman; Lynn From; Pamela A Groben; Bruce K Armstrong; Hoda Anton-Culver; Stephen B Gruber; Loraine D Marrett; Richard P Gallagher; Roberto Zanetti; Stefano Rosso; Terence Dwyer; Alison Venn; Peter A Kanetsky; Irene Orlow; Susan Paine; David W Ollila; Anne S Reiner; Li Luo; Honglin Hao; Jill S Frank; Colin B Begg; Marianne Berwick
Journal:  JAMA Dermatol       Date:  2014-12       Impact factor: 10.282

8.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

9.  Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4.

Authors:  P Waterhouse; J M Penninger; E Timms; A Wakeham; A Shahinian; K P Lee; C B Thompson; H Griesser; T W Mak
Journal:  Science       Date:  1995-11-10       Impact factor: 47.728

10.  Comparative profiles of BRAF inhibitors: the paradox index as a predictor of clinical toxicity.

Authors:  Charles H Adelmann; Grace Ching; Lili Du; Rachael C Saporito; Varun Bansal; Lindy J Pence; Roger Liang; Woojin Lee; Kenneth Y Tsai
Journal:  Oncotarget       Date:  2016-05-24
View more
  6 in total

1.  Andrographolide inhibits proliferation and induces cell cycle arrest and apoptosis in human melanoma cells.

Authors:  Guo Liu; Haihan Chu
Journal:  Oncol Lett       Date:  2018-02-02       Impact factor: 2.967

2.  M1-like macrophages change tumor blood vessels and microenvironment in murine melanoma.

Authors:  Magdalena Jarosz-Biej; Natalia Kamińska; Sybilla Matuszczak; Tomasz Cichoń; Jolanta Pamuła-Piłat; Justyna Czapla; Ryszard Smolarczyk; Daria Skwarzyńska; Klaudia Kulik; Stanisław Szala
Journal:  PLoS One       Date:  2018-01-10       Impact factor: 3.240

3.  Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.

Authors:  Carlos R Figueiredo; Ricardo A Azevedo; Sasha Mousdell; Pedro T Resende-Lara; Lucy Ireland; Almudena Santos; Natalia Girola; Rodrigo L O R Cunha; Michael C Schmid; Luciano Polonelli; Luiz R Travassos; Ainhoa Mielgo
Journal:  Front Immunol       Date:  2018-05-23       Impact factor: 7.561

4.  Joint action of miR-126 and MAPK/PI3K inhibitors against metastatic melanoma.

Authors:  Francesca Pedini; Gabriele De Luca; Federica Felicetti; Rossella Puglisi; Alessandra Boe; Maria Beatrice Arasi; Federica Fratini; Gianfranco Mattia; Massimo Spada; Simona Caporali; Mauro Biffoni; Alessandro Giuliani; Alessandra Carè; Nadia Felli
Journal:  Mol Oncol       Date:  2019-08-06       Impact factor: 6.603

Review 5.  Current state of melanoma diagnosis and treatment.

Authors:  Lauren E Davis; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2019-08-01       Impact factor: 4.742

6.  Lithraea caustic (Litre) Extract Promotes an Antitumor Response Against B16 Melanoma.

Authors:  Claudia Robles-Planells; Sofia A Michelson; Javier Mena; Daniela Escrig; Juan L Rojas; Giselle Sanchez-Guerrero; Ronny Hernández; Carlos Barrera-Avalos; Leonel E Rojo; Daniela Sauma; Alexis M Kalergis; Mónica Imarai; Ricardo Fernández; Carolina A Robles; Elías Leiva-Salcedo; Rocio Santander; Alejandro Escobar; Claudio Acuña-Castillo
Journal:  Front Pharmacol       Date:  2019-10-22       Impact factor: 5.810
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.